Budget Impact Analysis of Venetoclax for Management of Acute Myeloid Leukemia from the Perspective of the Social Security and the Private Sector in Argentina
Author(s)
Palacios A1, Espinola N2, Gonzalez JM2, Rivas MM3, Rojas-Roque C2, Kanevsky D4, Morisset P4, Augustovski F2, Pichon-Riviere DA2, Bardach A2
1Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 2Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, B, Argentina, 3Hospital Universitario Austral, Pilar, Argentina, 4Abbvie, Buenos Aires, Argentina
Presentation Documents
OBJECTIVES: This study aimed to estimate the budget impact of venetoclax incorporation for treatment of patients with acute myeloid leukemia (AML) (a rare disease) over 65 years of age or those with comorbidities contraindication for the use of intensive chemotherapy, from the perspective of the social security and the private healthcare sector in Argentina. METHODS: A budget impact model was programmed to estimate the cost difference between the current scenario (azacitidine, decitabine and low doses of cytarabine) and the new scenario (incorporation of venetoclax in combination) for a third-party payer over three years. Input parameters were obtained from a literature review, complemented by expert opinion using the modified Delphi method. Healthcare costs were estimated by the microcosting approach in September 2020. A one-way sensitivity analysis was conducted. RESULTS: The incidence of AML in people over 65 years was estimated at 20.1 cases per 100,000 individuals-year. For a cohort of 1,000,000 individuals covered by a social security third-party payer (with 20% of its population over 65 years of age), incorporating venetoclax implied an average absolute budget impact per year of ARS 11,927,006 (USD 157,671) and an average budget impact per member per month (PMPM) of ARS 0.99 (USD 0.013). For the private sector third-party payer (with 5% of its population over 65 years of age), incorporating venetoclax implied an average absolute budget impact per year of ARS 1,390,368 (USD 18,380) and an average budget impact PMPM of ARS 0.12 (USD 0.002). The duration of treatment with venetoclax was the most influential parameter in the budget impact results. CONCLUSIONS: The incorporation of venetoclax was associated with a slight cost increase in the social security and the private sector in Argentina, with the extended treatment duration being the most influential factor.
Conference/Value in Health Info
2021-11, ISPOR Europe 2021, Copenhagen, Denmark
Value in Health, Volume 24, Issue 12, S2 (December 2021)
Code
POSB43
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Drugs, Oncology, Rare and Orphan Diseases